These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15876807)

  • 1. Analysis of circulating apoptosis mediators and proinflammatory cytokines in patients with idiopathic hypertrophic cardiomyopathy: comparison between nonobstructive and dilated-phase hypertrophic cardiomyopathy.
    Zen K; Irie H; Doue T; Takamiya M; Yamano T; Sawada T; Azuma A; Matsubara H
    Int Heart J; 2005 Mar; 46(2):231-44. PubMed ID: 15876807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study of the roles of cytokines and apoptosis in dilated and hypertrophic cardiomyopathies.
    Buzás K; Megyeri K; Hõgye M; Csanády M; Bogáts G; Mándi Y
    Eur Cytokine Netw; 2004; 15(1):53-9. PubMed ID: 15217753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure.
    Nishigaki K; Minatoguchi S; Seishima M; Asano K; Noda T; Yasuda N; Sano H; Kumada H; Takemura M; Noma A; Tanaka T; Watanabe S; Fujiwara H
    J Am Coll Cardiol; 1997 May; 29(6):1214-20. PubMed ID: 9137215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure.
    Adamopoulos S; Parissis J; Karatzas D; Kroupis C; Georgiadis M; Karavolias G; Paraskevaidis J; Koniavitou K; Coats AJ; Kremastinos DT
    J Am Coll Cardiol; 2002 Feb; 39(4):653-63. PubMed ID: 11849865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proinflammatory cytokine activation is linked to apoptotic mediator, soluble Fas level in patients with chronic heart failure.
    Kinugawa T; Kato M; Yamamoto K; Hisatome I; Nohara R
    Int Heart J; 2012; 53(3):182-6. PubMed ID: 22790687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth hormone administration reduces circulating proinflammatory cytokines and soluble Fas/soluble Fas ligand system in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy.
    Adamopoulos S; Parissis JT; Georgiadis M; Karatzas D; Paraskevaidis J; Kroupis C; Karavolias G; Koniavitou K; Kremastinos DT
    Am Heart J; 2002 Aug; 144(2):359-64. PubMed ID: 12177657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of circulating levels of interleukin-6 and tumor necrosis factor-alpha in hypertrophic cardiomyopathy and in idiopathic dilated cardiomyopathy.
    Högye M; Mándi Y; Csanády M; Sepp R; Buzás K
    Am J Cardiol; 2004 Jul; 94(2):249-51. PubMed ID: 15246916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cytokines and remodeling of the heart in patients with congestive heart failure].
    Jołda-Mydłowska B; Salomon P
    Pol Arch Med Wewn; 2003 Jan; 109(1):23-33. PubMed ID: 12879763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of aetiology on inflammatory and neurohumoral activation in patients with severe heart failure: a prospective study comparing Chagas' heart disease and idiopathic dilated cardiomyopathy.
    Mocelin AO; Issa VS; Bacal F; Guimarães GV; Cunha E; Bocchi EA
    Eur J Heart Fail; 2005 Aug; 7(5):869-73. PubMed ID: 16043406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth hormone-induced reduction of soluble apoptosis mediators is associated with reverse cardiac remodelling and improvement of exercise capacity in patients with idiopathic dilated cardiomyopathy.
    Parissis JT; Adamopoulos S; Karatzas D; Paraskevaidis J; Livanis E; Kremastinos D
    Eur J Cardiovasc Prev Rehabil; 2005 Apr; 12(2):164-8. PubMed ID: 15785303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD.
    Yasuda N; Gotoh K; Minatoguchi S; Asano K; Nishigaki K; Nomura M; Ohno A; Watanabe M; Sano H; Kumada H; Sawa T; Fujiwara H
    Respir Med; 1998 Aug; 92(8):993-9. PubMed ID: 9893764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased circulating soluble form of Fas in patients with dilated cardiomyopathy.
    Kawakami H; Shigematsu Y; Ohtsuka T; Okayama H; Hayashi Y; Hara Y; Kodama K; Hamada M; Hiwada K
    Jpn Circ J; 1998 Dec; 62(12):873-6. PubMed ID: 9890197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble fas levels correlate with multiple organ dysfunction severity, survival and nitrate levels, but not with cellular apoptotic markers in critically ill patients.
    Papathanassoglou ED; Moynihan JA; Vermillion DL; McDermott MP; Ackerman MH
    Shock; 2000 Aug; 14(2):107-12. PubMed ID: 10947151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma soluble fas and soluble fas ligand in chronic glomerulonephritis.
    Sano H; Asano K; Minatoguchi S; Hiraoka J; Fujisawa K; Nishigaki K; Yasuda N; Kumada H; Takemura M; Ohashi H; Seishima M; Fujiwara T; Fujiwara H
    Nephron; 1998 Oct; 80(2):153-61. PubMed ID: 9736812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Examination of soluble Fas (sFas) and soluble Fas ligand (sFasL) in patients with burns.
    Yamada Y; Endo S; Nakae H; Makabe H; Sato N; Wakabayashi G; Kitamura M; Inada K; Sato S
    Burns; 2003 Dec; 29(8):799-802. PubMed ID: 14636754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of serum soluble Fas/soluble Fas ligand and TNF-alpha on response to interferon-alpha therapy in chronic hepatitis C.
    Toyoda M; Kakizaki S; Horiguchi N; Sato K; Takayama H; Takagi H; Nagamine T; Mori M
    Liver; 2000 Jul; 20(4):305-11. PubMed ID: 10959809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased circulating cytokines in patients with myocarditis and cardiomyopathy.
    Matsumori A; Yamada T; Suzuki H; Matoba Y; Sasayama S
    Br Heart J; 1994 Dec; 72(6):561-6. PubMed ID: 7857740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased plasma levels of adrenomedullin in patients with hypertrophic cardiomyopathy: its relation to endothelin-I, natriuretic peptides and noradrenaline.
    Hamada M; Shigematsu Y; Kawakami H; Minamino N; Kangawa K; Matsuo H; Hiwada K
    Clin Sci (Lond); 1998 Jan; 94(1):21-8. PubMed ID: 9505862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ongoing myocardial damage in chronic heart failure is related to activated tumor necrosis factor and Fas/Fas ligand system.
    Setsuta K; Seino Y; Ogawa T; Ohtsuka T; Seimiya K; Takano T
    Circ J; 2004 Aug; 68(8):747-50. PubMed ID: 15277733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The coagulation system is activated in idiopathic cardiomyopathy.
    Yamamoto K; Ikeda U; Furuhashi K; Irokawa M; Nakayama T; Shimada K
    J Am Coll Cardiol; 1995 Jun; 25(7):1634-40. PubMed ID: 7539015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.